Skip to main content
SpringerLink
Log in

Influence of the MIF polymorphism −173G > C on Turkish postmenopausal women with osteoporosis

Einfluss des MIF-Polymorphismus −173G > C auf türkische postmenopausale Frauen mit Osteoporose

  • Originalie
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

Abstract

Background

MIF, a proinflammatory cytokine, contributes to the pathogenesis of acute, chronic, and autoimmune inflammatory disorders and balances the suppressive effect of glucocorticoids on the immune system. There is an interaction between bone metabolism and the immune system via the production of cytokines. We aimed to analyze the relationship between the MIF gene −173G > C promoter polymorphism and osteoporosis.

Methods

In this case–control study performed in a university hospital, 286 samples (136 women with osteoporosis and 150 healthy age-matched controls) participated. The polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) assay was used to genotype the MIF gene polymorphism. The alleles and genotypes frequencies of patients and controls were compared using the χ2 test.

Results

The genotype frequencies of MIF gene −173G > C polymorphism showed statistically significant differences between patients and controls (p = 0.038). Also, the subjects carrying the variant C allele in the MIF −173 position were at significantly higher risk of osteoporosis than subjects carrying the wild-type G allele (p = 0.009, odds ratio 1.7, 95% confidence interval 1.1–2.6).

Conclusion

Our study suggested a strong association between MIF gene −173G > C polymorphism and osteoporosis in a Turkish population.

Zusammenfassung

Hintergrund

Das proinflammatorische Zytokin MIF ist an der Pathogenese akuter, chronischer und autoimmuner entzündlicher Erkrankungen beteiligt und trägt zur Balance des hemmenden Effekts von Glukokortikoiden auf das Immunsystem bei. Zwischen Knochenmetabolismus und Immunsystem besteht eine Wechselwirkung über die Bildung von Zytokinen. Ziel unserer Studie war es, die Beziehung zwischen dem MIF-Promotor-Polymorphismus −173G > C und Osteoporose zu untersuchen.

Methoden

An dieser Fall-Kontroll-Studie an einem Universitätsklinikum nahmen 286 Probanden teil (136 Frauen mit Osteoporose und 150 Kontrollpersonen im entsprechenden Alter). Mithilfe eines Polymerase-Kettenreaktions-basierten Assays für Restriktionsfragmentlängenpolymorphismen (PCR-RFLP) wurde der MIF-Polymorphismus genotypisiert. Die Allel- und Genotyphäufigkeiten der Patienten und Kontrollpersonen wurden unter Anwendung des χ2-Tests verglichen.

Ergebnisse

Die Genotyphäufigkeiten des MIF-Polymorphismus −173G > C zeigten statistisch signifikante Unterschiede zwischen Patienten und Kontrollpersonen (p = 0,038). Zudem wiesen die Studienteilnehmer mit Variante-C-Allel in der MIF-−173-Position ein signifikant höheres Osteoporoserisiko auf als Personen mit Wildtyp-G-Allel (p = 0,009, Odds Ratio 1,7; 95%-Konfidenzintervall 1,1–2,6).

Schlussfolgerung

Unsere Studienergebnisse deuten auf eine starke Assoziation zwischen dem MIF-Polymorphismus −173G > C und Osteoporose in einer türkischen Population hin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Orimo H, Nakamura T, Hosoi T et al (2012) Japanese 2011 guidelines for prevention and treatment of osteoporosis-executive summary. Arch Osteoporos 7:3–20

    Article  PubMed  PubMed Central  Google Scholar 

  2. Takayanagi H (2007) Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 7:292–304

    Article  PubMed  CAS  Google Scholar 

  3. Dewhirst FE, Stashenko PP, Mole JE, Tsurumachi T (1985) Purification and partial sequence of human osteoclast-activating factor: identity with interleukin 1 beta. J Immunol 135:2562–2568

    PubMed  CAS  Google Scholar 

  4. Takayanagi H, Ogasawara K, Hida S et al (2000) T‑cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 408:600–605

    Article  PubMed  CAS  Google Scholar 

  5. Calandra T, Bucala R (1995) Macrophage migration inhibitory factor: a counter-regulator of glucocorticoid action and critical mediator of septic shock. J Inflamm 47:39–51

    PubMed  CAS  Google Scholar 

  6. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR (1986) Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 319:516–518

    Article  PubMed  CAS  Google Scholar 

  7. Onodera S, Nishihira J, Iwabuchi K et al (2002) Macrophage migration inhibitory factor up-regulates matrix metalloproteinase-9 and -13 in rat osteoblasts.Relevance to intracellular signaling pathways. J Biol Chem 277:7865–7874

    Article  PubMed  CAS  Google Scholar 

  8. Onodera S, Sasaki S, Ohshima S et al (2006) Transgenic mice overexpressing macrophage migration inhibitory factor (MIF) exhibit high-turnover osteoporosis. J Bone Miner Res 21:876–885

    Article  PubMed  CAS  Google Scholar 

  9. Oshima S, Onodera S, Amizuka N et al (2006) Macrophage migration inhibitory factor-deficient mice are resistant to ovariectomyinduced bone loss. FEBS Lett 580:1251–1256

    Article  PubMed  CAS  Google Scholar 

  10. Onodera S, Nishihira J, Yamazaki M, Ishibashi T, Minami A (2004) Increased expression of macrophage migration inhibitory factor during fracture healing in rats. Histochem Cell Biol 121:209–217

    Article  PubMed  CAS  Google Scholar 

  11. Leech M, Metz C, Hall P et al (1999) Macrophage migration inhibitory factor in rheumatoid arthritis: evidence ofproinflammatory function and regulation by glucocorticoids. Arthritis Rheum 42:1601–1608

    Article  PubMed  CAS  Google Scholar 

  12. Meazza C, Travaglino P, Pignatti P et al (2002) Macrophage migration inhibitory factor in patients with juvenile idiopathic arthritis. Arthritis Rheum 46:232–237

    Article  PubMed  Google Scholar 

  13. Onodera S, Tanji H, Suzuki K et al (1999) High expression ofmacrophage migration inhibitory factor in the synovial tissues of rheumatoid joints. Cytokine 11:163–167

    Article  PubMed  CAS  Google Scholar 

  14. Donn R, Alourfi Z, De Benedetti F et al (2002) Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheum 46:2402–2409

    Article  PubMed  CAS  Google Scholar 

  15. Baugh JA, Chitnis S, Donnelly SC et al (2002) Functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) geneassociated with disease severity in rheumatoid arthritis. Genes Immun 3:170–176

    Article  PubMed  CAS  Google Scholar 

  16. Renner P, Roger T, Calandra T (2005) Macrophage migration inhibitory factor: gene polymorphisms and susceptibility to inflammatory diseases. Clin Infect Dis 41(Suppl 7):513–519

    Article  Google Scholar 

  17. Radstake TR, Sweep FC, Welsing P et al (2005) Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum 52:3020–3029

    Article  PubMed  CAS  Google Scholar 

  18. Bucala R (2006) MIF and the Genetic Basis of Macrophage Responsiveness. Curr Immunol Rev 2:217-223

    Article  CAS  Google Scholar 

  19. Gregersen PK, Bucala R (2003) Macrophage migration inhibitory factor, MIF alleles, and the genetics of inflammatory disorders: incorporating disease outcome into the definition of phenotype. Arthritis Rheum 48:1171–1176

    Article  PubMed  CAS  Google Scholar 

  20. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO Study Group (1994) Organization Technical Report Series. World Health 843:1–129

    Google Scholar 

  21. Wang FF, Huang XF, Shen N et al (2013) A genetic role for macrophage migration inhibitory factor (MIF) in adult-onset Still’s disease. Arthritis Res Ther 15(3):R65

  22. Calandra T, Roger T (2003) Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 3:791–800

    Article  PubMed  CAS  Google Scholar 

  23. Gregory JL, Morand EF, Mckeown SJ et al (2006) Macrophage migration inhibitory factor induces macrophage recruitment via CC chemokine ligand 2. J Immunol 177:8072–8079

    Article  PubMed  CAS  Google Scholar 

  24. Morand EF, Leech M, Bemhagen J (2006) MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis. Nat Rev Drug Discov 5:399–410

    Article  PubMed  CAS  Google Scholar 

  25. Tillmann S, Bernhagen J, Noels H (2013) Arrest Functions of the MIF Ligand/Receptor Axes in Atherogenesis. Front Immunol 16:115

    Google Scholar 

  26. Makino A, Nakamura T, Hirano M et al (2010) High plasma levels of macrophage migration inhibitory factor are associated with adverse long-term outcome in patients with stable coronary artery disease and impaired glucose tolerance or type 2 diabetes mellitus. Atherosclerosis 213:573–578

    Article  PubMed  CAS  Google Scholar 

  27. Ma L, Xue HB, Guan XH et al (2013) Relationship of macrophage migration inhibitory factor levels in PBMCs, lesional skin and serum with disease severity and anctvity in vitiligo vulgaris. Braz J Med Biol Res 46:460–464

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Swanberg M, McGuigan F, Ivaska KK et al (2010) Polymorphisms in the macrophage migration inhibitory factor gene and bone loss in postmenopausal women. Bone 47(2):424–429

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  29. Martínez A, Orozco G, Varadé J, López MS et al (2007) Macrophage migration inhibitory factor gene: influence on rheumatoid arthritis susceptibility. Hum Immunol 68:744–747

    Article  PubMed  CAS  Google Scholar 

  30. Barton A, Lamb R, Symmons D et al (2003) Macrophage migration inhibitory factor (MIF) gene polymorphism is associated with susceptibility to but not severity of inflammatory polyarthritis. Genes Immun 4:487–491

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by Gaziosmanpasa University (Project No. 2013/09).

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Gaziosmanpasa University, Faculty of Medicine, Tokat, Turkey

    A. Z. Ozsoy

  2. Department of Medical Biology, Gaziosmanpasa University, Faculty of Medicine, Tokat, Turkey

    N. Karakus & S. Yigit

  3. Department of Medical Biology, Ondokuz Mayis University, Faculty of Medicine, Samsun, Turkey

    S. Tural & N. Kara

  4. Department of Physical Medicine and Rehabilitation, Ondokuz Mayis University, Faculty of Medicine, Samsun, Turkey

    G. Alayli & O. Kuru

  5. Department of Oral and Maxillofacial Surgery, Gaziosmanpasa University, Faculty of Dentistry, Tokat, Turkey

    M. K. Tumer

Authors
  1. A. Z. Ozsoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Karakus
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Tural
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Yigit
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N. Kara
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Alayli
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. K. Tumer
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. O. Kuru
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. Karakus.

Ethics declarations

Conflict of interest

A. Z. Ozsoy, N. Karakus, S. Tural, S. Yigit, N. Kara, G. Alayli, M. K. Tumer and O. Kuru declare that they have no competing interests.

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Redaktion

U. Müller-Ladner, Bad Nauheim

U. Lange, Bad Nauheim

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ozsoy, A.Z., Karakus, N., Tural, S. et al. Influence of the MIF polymorphism −173G > C on Turkish postmenopausal women with osteoporosis. Z Rheumatol 77, 629–632 (2018). https://doi.org/10.1007/s00393-017-0382-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-017-0382-5

Keywords

Schlüsselwörter

Search

Navigation